Pharma Legislation: From Pricing To Patents
You may also be interested in...
KEI vows to continue battle over Bayh-Doyle restrictions after US Commerce Department suggests it may issue regulations to exclude pricing as a basis for requiring companies to license their patents.
House Ways & Means Committee clears legislation requiring manufacturers to justify 10% WAC increase in one year and 25% increase over three years, and to report number of free product samples.
Republican House Energy and Commerce Committee members say potentially taking a company's revenue for blocking a generic company from obtaining samples, rather than profit, is excessive.